Europese Unie - Deens - EMA (European Medicines Agency)

accord healthcare s.l.u. - leuprorelin mesilate - prostatiske neoplasmer - endokrine terapi - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Europese Unie - Deens - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - spesolimab - psoriasis - immunosuppressiva - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.

Europese Unie - Deens - EMA (European Medicines Agency)

extrovis eu ltd. - lacosamid - epilepsi - antiepileptika, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Europese Unie - Deens - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - respiratoriske syncytiale virusinfektioner - vacciner - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. se afsnit 4. 2 og 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. brug af denne vaccine bør være i overensstemmelse med de officielle anbefalinger.

Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - protaminsulfat - injektions-/infusionsvæske, opløsning - 10 mg/ml

Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

leo pharma a/s - protaminsulfat - injektions-/infusionsvæske, opløsning - 10 mg/ml

Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - protaminsulfat - injektions-/infusionsvæske, opløsning - 10 mg/ml

Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

abacus medicine a/s - protaminsulfat - injektions-/infusionsvæske, opløsning - 10 mg/ml

Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - protaminsulfat - injektions-/infusionsvæske, opløsning - 10 mg/ml

Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

medac gesellschaft für klinische - dinatriumlevofolinat - injektions-/infusionsvæske, opløsning - 50 mg/ml